2018
DOI: 10.15347/wjs/2018.003
|View full text |Cite
|
Sign up to set email alerts
|

ShK toxin: history, structure and therapeutic applications for autoimmune diseases

Abstract: Stichodactyla toxin (ShK) is a 35-residue basic peptide from the sea anemone Stichodactyla helianthus that blocks a number of potassium channels.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 91 publications
0
4
0
Order By: Relevance
“…The SHK domain was first identified in a potassium channel inhibitor from a sea anemone [91, 92]. A total of 125 SHK domains in 24 genes were identified in L. salmonis which is an extreme number for any arthropod species.…”
Section: Resultsmentioning
confidence: 99%
“…The SHK domain was first identified in a potassium channel inhibitor from a sea anemone [91, 92]. A total of 125 SHK domains in 24 genes were identified in L. salmonis which is an extreme number for any arthropod species.…”
Section: Resultsmentioning
confidence: 99%
“…They bind to all four subunits in the channel tetramer by two key interactions within the external vestibule – Lys22 occludes the channel pore like a “cork in a bottle,” and Tyr23, together with Lys22, forms a “functional dyad” required for channel block. Many K + channel-blocking peptides exhibit similar blocking mechanism, consisting of a dyad of lysine and neighboring aromatic/aliphatic residue (Chang et al, 2018). With the goal of developing a highly selective K v 1.3 inhibitor, nearly 10 years of effort was made to re-engineer the native ShK.…”
Section: Venom Peptides Targeting Potassium Channelsmentioning
confidence: 99%
“…Due to its effect on effector T cells, this protein became an attractive therapeutic candidate in treating autoimmune diseases [ 2 , 21 ]. One of the ShK-domain-containing proteins from sea anemone was developed as the drug Dalazatide and is currently under phase 1b clinical trials for the treatment of plaque psoriasis, a common autoimmune skin lesion [ 4 , 25 , 26 , 27 , 28 ].…”
Section: Introductionmentioning
confidence: 99%